Renaissance Capital’s CG Oncology CGON Stock Holding History

Renaissance Capital’s Portfolio CGON Stock Details CGON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.93M	Buy	+27,173	New	+$2M	1.33%	17

Other funds holding CGON

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

AMI Asset Management Los Angeles, California $1.74B AUM 24.77% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Indivisible Partners Clearwater, Florida $2.18B AUM 33.61% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

GF Fund Management Guangzhou, China $7.72B AUM 122.96% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Strengthening Families & Communities LLC Boston, Massachusetts $459M AUM 29.64% 1-Year Est. Return

Renaissance Capital's CGON Position: Q3 2026 in Review

Renaissance Capital opened a new position in CG Oncology (CGON) in Q3 2026: 27,173 shares worth $1.93M. The stake represents 1.33% of the portfolio and ranks #17 among its holdings.

25 funds tracked by Wall St. Rank hold CGON as of Q3 2026.

Renaissance Capital held 27,173 shares of CG Oncology worth $1.93M as of Q3 2026.
CG Oncology was a new Renaissance Capital position in Q3 2026.
CG Oncology made up 1.33% of Renaissance Capital's portfolio in Q3 2026, its #17 holding.
25 funds tracked by Wall St. Rank held CG Oncology as of Q3 2026.

Based on Renaissance Capital's 13F filing for Q3 2026, filed 23 Oct 2026.